Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDURANCE-3
2015-002272-24Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of glecaprevir, pibrentasvir, sofosbuvir and daclatasvir in chronic hepatitis C (CHC) (3 arms), sponsored by AbbVie Inc. Primary endpoint: SVR12 rate. Started Oct 2015; status: completed.
02
Drugs
glecaprevirpibrentasvirsofosbuvirdaclatasvir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2015-002272-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002272-24.